IO Biotech Email Format
Biotechnology ResearchHovedstaden, Denmark11-50 Employees
IO Biotech is a clinical-stage biotechnology company focused on developing immune-modulating, off-the-shelf therapeutic cancer vaccines using its T-win platform. The T-win platform is designed to activate T cells to attack both tumor cells and immune-suppressive cells in the tumor microenvironment. Its lead cancer vaccine candidate, Cylembio, is in clinical trials, while additional vaccine candidates are advancing through preclinical development. Headquartered in Copenhagen, Denmark, IO Biotech also maintains a US headquarters in New York and employs between 11 and 50 people. The company has pursued public financing, completing an initial public offering in 2021.